3.53
Schlusskurs vom Vortag:
$3.53
Offen:
$3.56
24-Stunden-Volumen:
5.59M
Relative Volume:
1.49
Marktkapitalisierung:
$707.19M
Einnahmen:
$314.00K
Nettoeinkommen (Verlust:
$-40.23M
KGV:
-12.61
EPS:
-0.28
Netto-Cashflow:
$-84.71M
1W Leistung:
+33.21%
1M Leistung:
+42.34%
6M Leistung:
+132.24%
1J Leistung:
+136.91%
Atai Life Sciences N V Stock (ATAI) Company Profile
Firmenname
Atai Life Sciences N V
Sektor
Branche
Telefon
49 89 2153 9035
Adresse
WALLSTRASSE 16, BERLIN
Vergleichen Sie ATAI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ATAI
Atai Life Sciences N V
|
3.53 | 562.18M | 314.00K | -40.23M | -84.71M | -0.28 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-18 | Bestätigt | H.C. Wainwright | Buy |
2024-04-03 | Hochstufung | Maxim Group | Hold → Buy |
2022-11-01 | Eingeleitet | Loop Capital | Buy |
2021-11-30 | Eingeleitet | Maxim Group | Buy |
2021-11-11 | Eingeleitet | ROTH Capital | Buy |
2021-10-18 | Eingeleitet | H.C. Wainwright | Buy |
2021-09-01 | Eingeleitet | Jefferies | Buy |
2021-07-13 | Eingeleitet | Berenberg | Buy |
2021-07-13 | Eingeleitet | Canaccord Genuity | Buy |
2021-07-13 | Eingeleitet | Cantor Fitzgerald | Buy |
2021-07-13 | Eingeleitet | Citigroup | Buy |
2021-07-13 | Eingeleitet | Cowen | Outperform |
2021-07-13 | Eingeleitet | Credit Suisse | Outperform |
2021-07-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2021-07-08 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Atai Life Sciences N V Aktie (ATAI) Neueste Nachrichten
Is Atai Life Sciences N.V. a good long term investmentHigh-octane financial growth - jammulinksnews.com
What drives Atai Life Sciences N.V. stock priceDynamic portfolio growth - jammulinksnews.com
5-HT2 Agonist Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - Yahoo Finance
What analysts say about Atai Life Sciences N.V. stockExplosive portfolio gains - Autocar Professional
atai Life Sciences Bets Big On Psychedelics For Mental Health - Finimize
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Atai Life Sciences N.V. Stock Analysis and ForecastFastest return on investment - jammulinksnews.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Why Atai Life Sciences N.V. stock attracts strong analyst attentionBreakout Momentum Stocks - beatles.ru
why atai life sciences n.v. stock attracts strong analyst attentionDaily Breakout Picks - Newser
How Atai Life Sciences N.V. stock performs during market volatilityMomentum Swing Watchlist - Newser
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - MSN
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target - Insider Monkey
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atai Life Sciences, Beckley Psytech Announce Positive Topline Results for BPL-003 - Yahoo Finance
13 Best German Stocks to Invest in Now - Insider Monkey
Retail investors are Atai Life Sciences N.V.'s (NASDAQ:ATAI) biggest owners and were rewarded after market cap rose by US$121m last week - Yahoo Finance
atai Life Sciences stock rating reiterated at Buy by Aegis Capital - Investing.com Australia
atai Life Sciences stock maintains Buy rating after positive Phase 2b results - Investing.com
atai Life Sciences stock price target raised to $12 by Canaccord on positive trial data - Investing.com Canada
Biotech Rips On Dual Announcement - The Globe and Mail
Atai Life Sciences’ Merger Sparks Market Buzz - timothysykes.com
Atai Life Sciences To Raise $50 Mln Via Private Placement To Fund Clinical Programs; Stock Up - Nasdaq
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression - GlobeNewswire
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June - Benzinga
Atai Life Sciences N.V. announced that it expects to receive $50 million in funding - MarketScreener
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? - Yahoo Finance
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
Psychedelic advocates hopeful Trump administration will support space, STAT says - Yahoo Finance
ATAI Sees Potential Boost from U.S. Policy Shift on Psychedelics - GuruFocus
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire Inc.
ATAI’s Stock Dilemma: ATAI Life Sciences N.V’s Market Performance and Outlook - investchronicle.com
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com
Finanzdaten der Atai Life Sciences N V-Aktie (ATAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):